scispace - formally typeset
O

Oliver Renner

Researcher at Carlos III Health Institute

Publications -  20
Citations -  2748

Oliver Renner is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Carcinogenesis. The author has an hindex of 16, co-authored 20 publications receiving 2525 citations.

Papers
More filters
Journal ArticleDOI

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

TL;DR: The data strongly support the view of the PTEN/PI3K/AKT pathway as an important target for drug discovery.
Journal ArticleDOI

Pericytes and the Pathogenesis of Diabetic Retinopathy

TL;DR: The pharmacological prevention of acellular capillaries without the rescue of pericyte loss in experimental diabetic retinopathy suggests that the endothelium is the primary therapeutic target.
Journal ArticleDOI

PTEN, more than the AKT pathway.

TL;DR: AKT is more than a passive bridge toward PTEN tumorigenesis, since its expression not only allows but also enforces and accelerates the tumorigenic process in combination with other oncogenes.
Journal ArticleDOI

Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy.

TL;DR: Data show that upregulation of angiopoietin-2 plays a critical role in the loss of pericytes in the diabetic retina, as well as preventing diabetes-induced pericyte loss and reducing the number of acellular capillary segments.
Journal ArticleDOI

Transcription profiling of platelet-derived growth factor-b-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells

TL;DR: To identify new markers for pericytes, the platelet-derived growth factor (PDGF)-B knockout mouse model is taken advantage, and RGS5, a member of the RGS family of GTPase-activating proteins for G proteins, is identified as a proof-of-principle.